» Articles » PMID: 8423332

Binding of Human Immunodeficiency Virus Type-1 to Follicular Dendritic Cells in Vitro is Complement Dependent

Overview
Journal J Immunol
Date 1993 Feb 1
PMID 8423332
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The authors studied the binding in vitro of HIV-1 virus particles, conjugated to fluorescein isothiocyanate, to follicular dendritic cells (FDC) isolated from human tonsils. Analysis was done using flow cytometry, fluorescence microscopy, and immunogold electron microscopy. The focus of study was on the effect of serum from various origins, including pooled fresh serum and heated serum from control donors and pooled heated serum from HIV-1-infected patients (containing anti-HIV-1 antibodies). In the presence of heated serum, either from controls or from HIV-1-infected patients, the fluorescence signal in flow cytometry was similar to the background value. In the presence of fresh serum, the signal was substantially increased, and an even higher signal was observed in the presence of fresh serum and serum from HIV-1-infected patients. This high fluorescence signal was also found in the presence of serum depleted of complement factor C5, but not with serum deficient in complement factor C3. The binding of HIV-1 virions to FDC in the presence of fresh serum was confirmed by fluorescence microscopy on cytospot preparations. After quenching of the extracellular fluorescence with trypan blue, the fluorescence was reduced to about 30% of the initial value, indicating that most of bound fluorescent virions were present extracellularly. Similar experiments using blood mononuclear cells showed that fluorescent HIV-1 particles after binding to these cells were present intracellularly. This flow cytometry data was confirmed in immunogold electron microscopy demonstrating that most HIV-1 gag p24 or FITC label was present at the outside of FDC and on adherent virus particles. We conclude that HIV-1 virions adhere to FDC in vitro in a complement component C3-dependent way. Anti-HIV-1 antibodies in serum from HIV-1 infected patients enhance binding but, by itself, are unable to mediate binding.

Citing Articles

CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.

Pampusch M, Abdelaal H, Cartwright E, Molden J, Davey B, Sauve J PLoS Pathog. 2022; 18(2):e1009831.

PMID: 35130312 PMC: 8853520. DOI: 10.1371/journal.ppat.1009831.


Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.

Haran K, Hajduczki A, Pampusch M, Mwakalundwa G, Vargas-Inchaustegui D, Rakasz E Front Immunol. 2018; 9:492.

PMID: 29616024 PMC: 5869724. DOI: 10.3389/fimmu.2018.00492.


Complement Evasion Strategies of Viruses: An Overview.

Agrawal P, Nawadkar R, Ojha H, Kumar J, Sahu A Front Microbiol. 2017; 8:1117.

PMID: 28670306 PMC: 5472698. DOI: 10.3389/fmicb.2017.01117.


Perspectives on Human Immunodeficiency Virus (HIV) Cure: HIV Persistence in Tissue.

Boritz E, Douek D J Infect Dis. 2017; 215(suppl_3):S128-S133.

PMID: 28520970 PMC: 5853386. DOI: 10.1093/infdis/jix005.


Are T cells the only HIV-1 reservoir?.

Kandathil A, Sugawara S, Balagopal A Retrovirology. 2016; 13(1):86.

PMID: 27998285 PMC: 5175311. DOI: 10.1186/s12977-016-0323-4.